Cargando…

Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients

Gastric cancer (GC) is one of the leading causes of malignancy-associated mortality worldwide. However, the underlying molecular mechanisms of GC are unclear and the prognosis of GC is poor. Therefore, it is important and urgent to explore the underlying mechanisms and screen for novel diagnostic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Tao, Wang, Danhua, Ping, Ying, Sang, Yiwen, Dai, Yibei, Wang, Yiyun, Liu, Zhenping, Duan, Xiuzhi, Tao, Zhihua, Liu, Weiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959404/
https://www.ncbi.nlm.nih.gov/pubmed/31894266
http://dx.doi.org/10.3892/ijo.2019.4944
_version_ 1783487590543917056
author Sun, Tao
Wang, Danhua
Ping, Ying
Sang, Yiwen
Dai, Yibei
Wang, Yiyun
Liu, Zhenping
Duan, Xiuzhi
Tao, Zhihua
Liu, Weiwei
author_facet Sun, Tao
Wang, Danhua
Ping, Ying
Sang, Yiwen
Dai, Yibei
Wang, Yiyun
Liu, Zhenping
Duan, Xiuzhi
Tao, Zhihua
Liu, Weiwei
author_sort Sun, Tao
collection PubMed
description Gastric cancer (GC) is one of the leading causes of malignancy-associated mortality worldwide. However, the underlying molecular mechanisms of GC are unclear and the prognosis of GC is poor. Therefore, it is important and urgent to explore the underlying mechanisms and screen for novel diagnostic and prognostic biomarkers, as well as therapeutic targets. In the current study, scale-free gene co-expression networks were constructed using weighted gene co-expression network analysis, the potential associations between gene sets and clinical features were investigated, and the hub genes were identified. The gene expression profiles of GSE38749 were downloaded from the Gene Expression Omnibus database. RNA-seq and clinical data for GC from The Cancer Genome Atlas were utilized for verification. Furthermore, the expression of candidate biomarkers in gastric tissues was investigated. Survival analysis was performed using Kaplan-Meier and log-rank test. The predictive role of candidate biomarkers in GC was evaluated using a receiver operator characteristic (ROC) curve. Gene Ontology, gene set enrichment analysis and gene set variation analysis methods were used to interpret the function of candidate biomarkers in GC. A total of 29 modules were identified via the average linkage hierarchical clustering. A significant module consisting of 48 genes associated with clinical traits was found; three genes with high connectivity in the clinical significant module were identified as hub genes. Among them, SLC5A6 and microfibril-associated protein 2 (MFAP2) were negatively associated with the overall survival, and their expression was elevated in GC compared with non-tumor tissues. Additionally, ROC curves indicated that SLC5A6 and MFAP2 showed a good diagnostic power in discriminating cancerous from normal tissues. SLC5A6 and MFAP2 were identified as novel diagnostic and prognostic biomarkers in GC patients; both of these genes were first reported here in connection with GC and deserved further research.
format Online
Article
Text
id pubmed-6959404
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-69594042020-01-30 Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients Sun, Tao Wang, Danhua Ping, Ying Sang, Yiwen Dai, Yibei Wang, Yiyun Liu, Zhenping Duan, Xiuzhi Tao, Zhihua Liu, Weiwei Int J Oncol Articles Gastric cancer (GC) is one of the leading causes of malignancy-associated mortality worldwide. However, the underlying molecular mechanisms of GC are unclear and the prognosis of GC is poor. Therefore, it is important and urgent to explore the underlying mechanisms and screen for novel diagnostic and prognostic biomarkers, as well as therapeutic targets. In the current study, scale-free gene co-expression networks were constructed using weighted gene co-expression network analysis, the potential associations between gene sets and clinical features were investigated, and the hub genes were identified. The gene expression profiles of GSE38749 were downloaded from the Gene Expression Omnibus database. RNA-seq and clinical data for GC from The Cancer Genome Atlas were utilized for verification. Furthermore, the expression of candidate biomarkers in gastric tissues was investigated. Survival analysis was performed using Kaplan-Meier and log-rank test. The predictive role of candidate biomarkers in GC was evaluated using a receiver operator characteristic (ROC) curve. Gene Ontology, gene set enrichment analysis and gene set variation analysis methods were used to interpret the function of candidate biomarkers in GC. A total of 29 modules were identified via the average linkage hierarchical clustering. A significant module consisting of 48 genes associated with clinical traits was found; three genes with high connectivity in the clinical significant module were identified as hub genes. Among them, SLC5A6 and microfibril-associated protein 2 (MFAP2) were negatively associated with the overall survival, and their expression was elevated in GC compared with non-tumor tissues. Additionally, ROC curves indicated that SLC5A6 and MFAP2 showed a good diagnostic power in discriminating cancerous from normal tissues. SLC5A6 and MFAP2 were identified as novel diagnostic and prognostic biomarkers in GC patients; both of these genes were first reported here in connection with GC and deserved further research. D.A. Spandidos 2019-12-16 /pmc/articles/PMC6959404/ /pubmed/31894266 http://dx.doi.org/10.3892/ijo.2019.4944 Text en Copyright: © Sun et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Sun, Tao
Wang, Danhua
Ping, Ying
Sang, Yiwen
Dai, Yibei
Wang, Yiyun
Liu, Zhenping
Duan, Xiuzhi
Tao, Zhihua
Liu, Weiwei
Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients
title Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients
title_full Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients
title_fullStr Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients
title_full_unstemmed Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients
title_short Integrated profiling identifies SLC5A6 and MFAP2 as novel diagnostic and prognostic biomarkers in gastric cancer patients
title_sort integrated profiling identifies slc5a6 and mfap2 as novel diagnostic and prognostic biomarkers in gastric cancer patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959404/
https://www.ncbi.nlm.nih.gov/pubmed/31894266
http://dx.doi.org/10.3892/ijo.2019.4944
work_keys_str_mv AT suntao integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients
AT wangdanhua integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients
AT pingying integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients
AT sangyiwen integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients
AT daiyibei integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients
AT wangyiyun integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients
AT liuzhenping integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients
AT duanxiuzhi integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients
AT taozhihua integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients
AT liuweiwei integratedprofilingidentifiesslc5a6andmfap2asnoveldiagnosticandprognosticbiomarkersingastriccancerpatients